Acquired Company

Pfizer completed acquisition of Trillium Therapeutics on November 17, 2021 for $18.50 per share in cash, representing an aggregate purchase price of approximately $2.22 billion.

Trillium is an immuno-oncology company developing innovative therapies for the treatment of cancer. The company’s two clinical programs, TTI-621 and TTI-622, target CD47, a “don’t eat me” signal that cancer cells frequently use to evade the immune system. Show more

Location: | Website: www.trilliumtherapeutics.com | Industry: Biological Product (except Diagnostic) Manufacturing | Sector: Manufacturing

Market Cap

0.00

52 Wk Range

$19.23 - $21.27

Previous Close

$19.81

Open

$19.83

Volume

565

Day Range

$19.83 - $19.90

Enterprise Value

0.00

Cash

0.00

Avg Qtr Burn

N/A

Insider Ownership

0.00%

Institutional Own.

0.00%

Qtr Updated

09/30/24

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date